MIMEDX GROUP, INC.

Listed Company

MDXGCIK 0001376339NasdaqLarge AcceleratedSurgical & Medical Instruments & ApparatusFY ends Dec 31

Period

FY 2025

Revenue

$418.63M

Net Income

$48.58M

Total Assets

$342.65M

Equity

$256.55M

Shares Out

148.95M

Op. Cash Flow

$74.00M

MDXG$4.31−35.77% · past yearDBEQ Basic

Daily closing prices

Business

MIMEDX Group, Inc. is a regenerative medicine company that manufactures and distributes placental allografts, xenografts, and other tissue-based products for advanced wound care, surgical, and burn applications. The company sources donated human birth tissues, processes them using its proprietary PURION method, and sells products including EPIFIX, EPICORD, EPIEFFECT, and HELIOGEN through direct sales teams, independent agents, and distributors. Primary markets include U.S. hospital outpatient departments, physician offices, ambulatory surgery centers, and international markets such as Japan.

Summary from 10-K filed 2026-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	419	349	321	268	242
Cost of sales	73	60	55	48	40
Gross profit	346	289	267	220	202
Selling, general and administrative	266	225	211	209	195
Research and development	15	12	13	13	10
Investigation, restatement and related	0	−9	5	12	—
Amortization of intangible assets	439,000	765,000	762,000	701,000	820,000
Impairment of intangible assets	0	400,000	0	0	100,000
Operating income	64	59	37	−15	−7
Interest income (expense), net	3	−1	−6	−5	—
Other expense, net	−558,000	−565,000	−26,000	−4,000	−23,000
Income from continuing operations before income tax	66	57	31	−20	−12
Income tax provision (expense) benefit from continuing operations	−18	−15	37	−206,000	−247,000
Net income from continuing operations	49	42	67	−20	−12
Income (loss) from discontinued operations, net of tax	0	421,000	−9	−10	2
Net income	49	42	58	−30	−10
Net income available to common stockholders from continuing operations	49	42	56	−27	−18
Continuing operations - basic (in dollars per share)	0.33	0.29	0.48	−0.24	−0.17
Discontinued operations - basic (in dollars per share)	0	0	−0.08	−0.09	0.02
Basic net income per common share (in dollars per share)	0.33	0.29	0.4	−0.33	−0.15
Continuing operations (in dollars per share)	0.32	0.28	0.43	−0.24	−0.17
Discontinued operations (in dollars per share)	0	0	−0.06	−0.09	0.02
Diluted net income (loss) per common share (in dollars per share)	0.32	0.28	0.37	−0.33	−0.15
Weighted average shares outstanding - basic (in shares)	148	147	116	113	110
Weighted average shares outstanding - diluted (in shares)	150	149	146	113	110

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	166	104	82	66	87
Accounts receivable, net	76	56	54	43	40
Inventory	25	24	21	13	11
Other current assets	10	8	2	3	3
Total current assets	277	192	164	134	149
Property and equipment, net	5	6	7	8	9
Deferred tax assets	20	28	41	0	—
Goodwill	19	19	19	19	19
Intangible assets, net	14	12	5	6	5
Other assets	7	7	205,000	148,000	186,000
Total assets	343	264	239	171	188
Current portion of long term debt	2	1	1	—	—
Accounts payable	15	7	9	8	7
Accrued compensation	31	24	22	21	24
Accrued expenses	11	9	9	11	10
Other current liabilities	6	5	3	2	2
Total current liabilities	64	46	46	44	42
Long term debt, net	16	18	48	49	48
Other liabilities	5	7	2	5	5
Total liabilities	86	71	96	97	95
Common stock; $.001 par value; 250,000,000 shares authorized, 148,093,920 issued and outstanding at December 31, 2025 and 146,932,032 issued and outstanding at December 31, 2024	148,000	147,000	146,000	114,000	113,000
Additional paid-in capital	299	284	276	174	166
Accumulated deficit	−43	−91	−134	−192	−162
Total stockholders equity	257	193	143	−18	82,000
Total liabilities and stockholders equity	343	264	239	171	188

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based compensation	16	17	17	11	14
Depreciation and amortization	15	6	3	—	—
Deferred income taxes	9	12	−38	0	0
Credit loss expense	7	595,000	1	3	0
Non-cash lease expenses	1	1	1	1	989,000
Shares received in settlement of litigation	0	−9	0	0	—
Loss on extinguishment of debt	0	1	0	0	0
Other	641,000	1	613,000	542,000	—
Accounts receivable	−26	−3	−12	−6	−11
Inventory	−2	−2	−8	−2	−1
Other assets	−9	−352,000	1	−333,000	10
Accounts payable	2	−1	783,000	839,000	−159,000
Accrued compensation	9	3	2	−2	5
Accrued expenses	2	−789,000	−2	2	−20
Other liabilities	289,000	−870,000	−497,000	75,000	−1
Net cash flows from operating activities of continuing operations	74	67	35	−8	−10
Net cash flows used in operating activities of discontinued operations	0	−930,000	−8	−10	8
Net cash flows provided by operating activities	74	66	27	−18	−2
Cash paid for acquisitions	−4	−8	0	0	—
Purchases of equipment	−1	−2	−2	−2	−3
Other investments	−2	−38,000	−168,000	−1	—
Net cash flows used in investing activities	−7	−10	−2	−3	−3
Stock repurchased for tax withholdings on vesting of restricted stock	−3	−3	0	−1	−5
Cash paid for Profit Share Payment (Note 14)	−1	−80,000	0	—	—
Proceeds from Citizens Revolving Credit Facility	0	30	0	0	—
Proceeds from Citizens Term Loan	0	20	0	0	—
Prepayment premium on previous term loan	0	−500,000	0	0	0
Deferred financing cost	0	−1	0	0	0
Repayment of previous term loan	0	−50	0	0	—
Repayment of Citizens Revolving Credit Facility	0	−30	0	0	—
Principal payments on Citizens Term Loan Facility	−1	−1	0	0	—
Proceeds from exercise of stock options	0	1	1	700,000	1
Repurchase of Series B Preferred Shares	0	0	−10	0	0
Other	0	−57,000	−52,000	−41,000	—
Net cash flows used in financing activities	−5	−34	−9	−580,000	−3
Net change in cash	62	22	16	−21	−9

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is MIMEDX GROUP, INC.'s CIK number?

MIMEDX GROUP, INC.'s SEC CIK number is 0001376339 (1376339). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find MIMEDX GROUP, INC.'s SEC filings?

All of MIMEDX GROUP, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did MIMEDX GROUP, INC. last report earnings?

MIMEDX GROUP, INC. (MDXG) most recently filed an earnings 8-K with the SEC on Apr 29, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001376339-26-000032). This is MIMEDX GROUP, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is MIMEDX GROUP, INC.'s most recent earnings 8-K?

MIMEDX GROUP, INC.'s latest earnings 8-K (Item 2.02) was filed Apr 29, 2026 under accession 0001376339-26-000032. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View MIMEDX GROUP, INC.'s latest earnings 8-K →
Look up any company's CIK number →